Unique patterns of metastases in common and rare types of malignancy

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 607-614

  Leong, Stanley P L ^a,i   Nakakura, Eric K ^b   Pollock, Raphael ^c   Choti, Michael A ^d   Morton, Donald L ^e   Henner, W David ^f   Lal, Anita ^f   Pillai, Raji ^f   Clark, Orlo H ^g   Cady, Blake ^h  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHN WAYNE CANCER INSTITUTE   (United States)

^f Pathwork Diagnostics   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CAMBRIDGE HOSPITAL   (United States)

ⁱ Sutter Pacific Medical Foundation   (United States)

Author keywords

cancer; metastases; patterns

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; GENETIC REGULATION; HUMAN; INCUBATION TIME; LIVER METASTASIS; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATIENT SELECTION; PRIORITY JOURNAL; RARE DISEASE; SENTINEL LYMPH NODE; SOFT TISSUE SARCOMA; THYROID CANCER; TREATMENT OUTCOME;

HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PANCREATIC NEOPLASMS; PROGNOSIS; SARCOMA; SURVIVAL RATE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953845515     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21841     Document Type: Article

References (99)

1. Leong SP, Zuber M, Ferris RL, et al.: Impact of nodal status and tumor burden in sentinel nodes on the clinical outcomes. Semin Surg Oncol 2011; ibid.
2. Cady B,: Regional lymph node metastases; a singular manifestation of the process of clinical metastases in cancer: Contemporary animal research and clinical reports suggest unifying concepts. Ann Surg Oncol 2007; 14: 1790-1800. (Pubitemid 46876511)
3. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
4. Nakakura EK, Yeo CJ,: Periampullary and pancreatic cancer. In:, Blumgart LH, editor. Surgery of the liver, biliary tract, and pancreas. Philadelphia, PA: Saunders Elsevier; 2007. pp. 849-857.
5. Nakakura EK, Warren RS,: Palliative care for patients with advanced pancreatic and biliary cancers. Surg Oncol 2007; 16: 293-297. (Pubitemid 350192230)
6. O'Morchoe CC,: Lymphatic system of the pancreas. Microsc Res Tech 1997; 37: 456-477. (Pubitemid 27294884)
7. Winter JM, Cameron JL, Campbell KA, et al.: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210 (discussion 1210-1211).
8. Katz MH, Wang H, Fleming JB, et al.: Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847.
9. Ferrone CR, Brennan MF, Gonen M, et al.: Pancreatic adenocarcinoma: The actual 5-year survivors. J Gastrointest Surg 2008; 12: 701-706.
10. Schnelldorfer T, Ware AL, Sarr MG, et al.: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg 2008; 247: 456-462.
11. Riall TS, Cameron JL, Lillemoe KD, et al.: Resected periampullary adenocarcinoma: 5-Year survivors and their 6- to 10-year follow-up. Surgery 2006; 140: 764-772. (Pubitemid 44648193)
12. Pedrazzoli S, DiCarlo V, Dionigi R, et al.: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517. (Pubitemid 30194394)
13. Henne-Bruns D, Vogel I, Luttges J, et al.: Surgery for ductal adenocarcinoma of the pancreatic head: Staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000; 24: 595-601 (discussion 601-602).
14. Farnell MB, Pearson RK, Sarr MG, et al.: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618-628 (discussion 628-630).
15. Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236: 366-368 (discussion 366-368).
16. Nimura Y, Nagino M, Kato H, et al.: Regional vs extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer. A multicenter randomized controlled trial (abstract). HPB 2004; 6: 2.
17. Evans DB, Farnell MB, Lillemoe KD, et al.: Surgical treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1736-1744.
18. Adam R, Chiche L, Aloia T, et al.: Hepatic resection for noncolorectal nonendocrine liver metastases: Analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-535.
19. Gleisner AL, Assumpcao L, Cameron JL, et al.: Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110: 2484-2492. (Pubitemid 350174934)
20. Tomlinson JS, Jain S, Bentrem DJ, et al.: Accuracy of staging node-negative pancreas cancer: A potential quality measure. Arch Surg 2007; 142: 767-773 (discussion 773-774). (Pubitemid 47295740)
21. Clark O,: Thyroid cancer and lymph node metastases. Semin Surg Oncol 2011; ibid.
22. Lahat G, Alexander L, Xuemei W, et al.: Increased VEGF-C expression is insufficient to induce lymphatic metastasis; insights from the study of human soft tissue sarcoma. Clin Cancer Res 2009; 15: 2637-2646.
23. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
24. Edwards BK, Howe HL, Ries LA, et al.: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94: 2766-2792. (Pubitemid 34478095)
25. Hess KR, Varadhachary GR, Taylor SH, et al.: Metastatic patterns in adenocarcinoma. Cancer 2006; 106: 1624-1633.
26. Bengmark S, Hafstrom L,: The natural course for liver cancer. Prog Clin Cancer 1978; 7: 195-200.
27. Oxley EM, Ellis H,: Prognosis of carcinoma of the large bowel in the presence of liver metastases. Br J Surg 1969; 56: 149-152.
28. Wood CB, Gillis CR, Blumgart LH,: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2: 285-288.
29. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946. (Pubitemid 27106275)
30. Gayowski TJ, Iwatsuki S, Madariaga JR, et al.: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-710 (discussion 710-711).
31. Hughes KS, Simon R, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278-284. (Pubitemid 16070861)
32. Jenkins LT, Millikan KW, Bines SD, et al.: Hepatic resection for metastatic colorectal cancer. Am Surg 1997; 63: 605-610. (Pubitemid 27268583)
33. Scheele J, Stangl R, Altendorf-Hofmann A,: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246.
34. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825 (discussion 825-827).
35. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766. (Pubitemid 34547293)
36. Fernandez FG, Drebin JA, Linehan DC, et al.: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447 (discussion 447-450).
37. Pawlik TM, Scoggins CR, Zorzi D, et al.: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-722 (discussion 722-724).
38. Gleisner AL, Choti MA, Assumpcao L, et al.: Colorectal liver metastases: Recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008; 143: 1204-1212.
39. Chua TC, Bester L, Saxena A, et al.: Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2010.
40. Fisher ER, Turnbull RB, Jr:, The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg Gynecol Obstet 1955; 100: 102-108.
41. Fisher ER, Fisher B,: Experimental studies of factors influencing the development of hepatic metastases. Xiii. Effect of hepatic trauma in parabiotic pairs. Cancer Res 1963; 23: 896-900.
42. Taylor I, Machin D, Mullee M, et al.: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359-363. (Pubitemid 15034705)
43. Wolmark N, Rockette H, Wickerham DL, et al.: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466-1475. (Pubitemid 20301177)
44. Weber W, Maibach R, Laffer U, et al.: Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Swiss Group for Clinical Cancer Research. Anticancer Res 1995; 15: 2197-2200. (Pubitemid 26031300)
45. Fukumura D, Yuan F, Monsky WL, et al.: Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997; 151: 679-688. (Pubitemid 27385599)
46. Fukumura D, Duda DG, Munn LL, et al.: Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17: 206-225.
47. Langley RR, Fidler IJ,: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007; 28: 297-321. (Pubitemid 46984829)
48. MacPhee PJ, Schmidt EE, Groom AC,: Intermittence of blood flow in liver sinusoids, studied by high-resolution in vivo microscopy. Am J Physiol 1995; 269: G692-G698.
49. Fidler IJ, Wilmanns C, Staroselsky A, et al.: Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 1994; 13: 209-222. (Pubitemid 24220006)
50. Takeda K, Hayakawa Y, Smyth MJ, et al.: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100. (Pubitemid 32095647)
51. Grimm M, Gasser M, Bueter M, et al.: Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer 2010; 10: 82.
52. Fritzmann J, Morkel M, Besser D, et al.: A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009; 137: 165-175.
53. Griffini P, Smorenburg SM, Vogels IM, et al.: Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver. Clin Exp Metastasis 1996; 14: 367-380. (Pubitemid 26363211)
54. Macartney-Coxson DP, Hood KA, Shi HJ, et al.: Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 Candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 2008; 8: 187.
55. Zucker S, Vacirca J,: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117. (Pubitemid 38221598)
56. Ahmed N, Oliva K, Wang Y, et al.: Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer 2003; 89: 374-384. (Pubitemid 36976329)
57. Schluter K, Gassmann P, Enns A, et al.: Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am J Pathol 2006; 169: 1064-1073. (Pubitemid 44411967)
58. Gout S, Huot J,: Role of cancer microenvironment in metastasis: Focus on colon cancer. Cancer Microenviron 2008; 1: 69-83.
59. Paku S, Dome B, Toth R, et al.: Organ-specificity of the extravasation process: An ultrastructural study. Clin Exp Metastasis 2000; 18: 481-492. (Pubitemid 32844249)
60. Takahashi Y, Kitadai Y, Bucana CD, et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
61. Warren RS, Yuan H, Matli MR, et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-1797.
62. Sondak B, Liu P, Warneke J,: Surgical resection for Stage IV melanoma: A Southwest Oncology Group Trial. J Clin Oncol 2006; 24: 8019.
63. Ricaniadis N, Konstadoulakis M, Walsh D, et al.: Gastrointestinal metastases from malignant melanoma. Surg Oncol 1995; 4: 105-110.
64. Ollila D, Essner R, Wanek L, et al.: Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996; 131: 975-980. (Pubitemid 26300099)
65. Agarwala S, Yao T, Coit D,: Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 1999; 336-344. (Pubitemid 29260795)
66. Harpole D Jr, Johnson C, Wolfe W, et al.: Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992; 103: 743-748 (discussion 8-50).
67. Leo F, Cagini L, Rocmans P, et al.: Lung metastases from melanoma: When is surgical treatment warranted? Br J Cancer 2000; 83: 569-572. (Pubitemid 30636294)
68. Tafra L, Dale P, Wanek L, et al.: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110: 119-128 (discussion 29).
69. Ollila D, Stern S, Morton DL,: Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol 1998; 69: 206-211. (Pubitemid 29024563)
70. Karakousis C, Velez A, Driscoll D, et al.: Metastasectomy in malignant melanoma. Surgery 1994; 115: 295-302. (Pubitemid 24098320)
71. Wong J, Skinner K, Kim K, et al.: The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993; 113: 389-394. (Pubitemid 23111532)
72. Fletcher W, Pommier R, Lum S, et al.: Surgical treatment of metastatic melanoma. Am J Surg 1998; 175: 413-417. (Pubitemid 28213457)
73. Ollila D, Hsueh E, Stern S, et al.: Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999; 71: 209-213. (Pubitemid 29388015)
74. Meyer T, Merkel S, Goehl J, et al.: Surgical therapy for distant metastases of malignant melanoma. Cancer 2000; 89: 1983-1991.
75. Ollila D,: Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 2006; 7: 919-924. (Pubitemid 44615951)
76. Pavlidis N, Fizazi K,: Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69: 271-278.
77. Bugat R, Bataillard A, Lesimple T, et al.: Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89: S59-S66. (Pubitemid 37076150)
78. Greco FA, Pavlidis N,: Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 2009; 36: 65-74.
79. Abbruzzese JL, Abbruzzese MC, Lenzi R, et al.: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
80. Hainsworth JD, Spigel DR, Farley C, et al.: Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25: 1747-1752. (Pubitemid 46797956)
81. Varadhachary GR, Talantov D, Raber MN, et al.: Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26: 4442-4448.
82. Varadhachary GR, Raber MN, Matamoros A, et al.: Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008; 9: 596-599. (Pubitemid 351722584)
83. Park SY, Kim BH, Kim JH, et al.: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131: 1561-1567.
84. Baker PM, Oliva E,: Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: An update. Int J Gynecol Pathol 2005; 24: 39-55. (Pubitemid 40066452)
85. McKenney JK, Amin MB,: The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol 2005; 22: 69-87. (Pubitemid 43163180)
86. Bahrami A, Truong LD, Ro JY,: Undifferentiated tumor: True identity by immunohistochemistry. Arch Pathol Lab Med 2008; 132: 326-348. (Pubitemid 351328809)
87. Brown RW, Campagna LB, Dunn JK, et al.: Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997; 107: 12-19. (Pubitemid 27104630)
88. Anderson GG, Weiss L,: Determining tissue of origin for metastatic cancers: Meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010; 1: 3-8.
89. Bloom G, Yang IV, Boulware D, et al.: Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004; 164: 9-16. (Pubitemid 38364584)
90. Ramaswamy S, Tamayo P, Rifkin R, et al.: Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001; 98: 15149-15154. (Pubitemid 34013984)
91. Su AI, Welsh JB, Sapinoso LM, et al.: Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-7393. (Pubitemid 32995021)
92. Tothill RW, Kowalczyk A, Rischin D, et al.: An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031-4040. (Pubitemid 40775639)
93. Bammler T, Beyer RP, Bhattacharya S, et al.: Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2005; 2: 351-356.
94. Dobbin KK, Beer DG, Meyerson M, et al.: Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 2005; 11: 565-572. (Pubitemid 40116881)
95. Irizarry RA, Warren D, Spencer F, et al.: Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2: 345-350.
96. Larkin JE, Frank BC, Gavras H, et al.: Independence and reproducibility across microarray platforms. Nat Methods 2005; 2: 337-344.
97. Pillai R, Deeter R, Rigi CT, et al.: Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed paraffin-embedded specimens. J Molec Diag 2011; 13: 48-56.
98. Dumur CI, Lyons-Weiler M, Sciulli C, et al.: Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 2008; 10: 67-77. (Pubitemid 351184837)
99. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al.: Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009; 27: 2503-2508.